Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

March 21, 2024

Primary Completion Date

March 21, 2027

Study Completion Date

March 21, 2029

Conditions
Low-grade Glioma
Interventions
DRUG

Tovorafenib

"Tovorafenib for oral dosing is provided as an immediate-release tablet in 100 mg strength. The 100 mg tablets are red to yellowish red oval tablets. All products are labeled tovorafenib. In addition, tovorafenib is provided as a powder for reconstitution (PfR) in bottles (430mg per bottle to deliver 300 mg dose). Upon reconstitution with water, the concentration is 25 mg/mL.~Vinblastine is administered by intravenous route as IV push, sites to follow local administration guidelines, once weekly (central line, but peripheral line is also permitted)"

DRUG

Vinblastine

vinblastine in combination with tovorafenib

Trial Locations (1)

M5G 1X8

RECRUITING

The Hospital for Sick Children, Toronto

All Listed Sponsors
collaborator

The Hospital for Sick Children

OTHER

lead

Daniel Morgenstern

OTHER